NDA 203137 · Ge Healthcare
Vizamyl
Flutemetamol F-18 · Intravenous · Radioactive Diagnostic Agent
NovelLast checked: Nov 20, 2026Latest source record: Jun 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Oct 25, 2013
Approved uses
2
Original approval plus efficacy supplements
Registered trials
9
1 Phase 3, 1 recruiting
FAERS reports
520
166 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 6, 2026.
VIZAMYL is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products VIZAMYL is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products ( 1 )
Mechanism: Flutemetamol F 18 binds to amyloid beta plaques in the brain and the F 18 isotope produces a positron signal that is detected by a PET scanner. In in vitro binding studies using postmortem human brain homogenates containing fibrillar amyloid beta, the dissociation constant (Kd) for flutemetamol was 6.7 nM. Selectivity of 3 H-flutemetamol binding in postmortem human brain sections was demonstrated using autoradiography, silver-stained protein, and immunohistochemistry (monoclonal antibody to amyloid beta) correlation studies.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 23, 2025 Supplement 24 · Efficacy LetterLabel
- Oct 25, 2013 Original approval · Type 1 - New Molecular Entity NovelReviewLabelLetter
2 products under this application
- VIZAMYL · FLUTEMETAMOL F-18 121.5mCi/30ML (4.05mCi/ML) · INJECTABLE, INTRAVENOUS · Prescription
- VIZAMYL · FLUTEMETAMOL F-18 40.5mCi/10ML (4.05mCi/ML) · INJECTABLE, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Flutemetamol F-18" as an intervention, any sponsor and status, largest first.
Mayo ClinicAcademic, hospital or other
NCT01607476 · 89 participants · Start Jul 2012 · Primary completion Dec 2014
Drug: C11 PiB; F18 Flutametamol · For: Alzheimer's Disease
Sites: Rochester, Minnesota
GE HealthcareIndustry
NCT02813070 · 70 participants · Start Oct 2012 · Primary completion May 2013
Drug: [18F] Flutemetamol · For: Mild Cognitive Impairment; Alzheimer's Disease; Healthy
- The Role of Large Artery Plaque Imaging Features in Predicting Inflammation and CognitionActive, not recruiting
Scott McnallyAcademic, hospital or other
NCT03068442 · 45 participants (planned) · Start Feb 17, 2017 · Primary completion Sep 10, 2030
Drug: Imaging with flutemetamol F 18 PET/CT · For: Cognitive Impairment; Carotid Artery Plaque; Inflammation
Sites: Salt Lake City, Utah · 2 sites in all
GE HealthcareIndustry
NCT07873463 · 20 participants (planned) · Start Sep 30, 2026 · Primary completion Feb 25, 2027
Drug: GE-287; Vizamyl and 2 more · For: Cognitive Dysfunction
Sites: Aventura, Florida; Merritt Island, Florida; Miami, Florida · 6 sites in all
University of UtahAcademic, hospital or other
NCT02317783 · 15 participants · Start Jan 31, 2018 · Primary completion Sep 24, 2019
Drug: [18F]Flutemetamol; [18F]fluoro-2-deoxy-D-glucose (FDG) · For: Breast Cancer
Sites: Salt Lake City, Utah
Yale UniversityAcademic, hospital or other
NCT05374564 · 12 participants · Start Aug 16, 2022 · Primary completion Nov 14, 2024
Drug: (18F)Flutemetamol · For: Cardiomyopathies, Primary
Sites: New Haven, Connecticut
- Investigating the Clinical Consequences of Flutemetamol-PET-scanningPivotal-lookingTerminated
University of ZurichAcademic, hospital or other
NCT02353949 · 11 participants · Start May 2015 · Primary completion Dec 10, 2019
Drug: Flutemetamol (Vizamyl) · For: Mild Cognitive Impairment; Alzheimer's Disease; Dementia
Sites: Schlieren, Switzerland
- Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.Terminated
University Hospital, ToulouseAcademic, hospital or other
NCT03232632 · 7 participants · Start Mar 15, 2017 · Primary completion Sep 15, 2019
Drug: PET with 18 F-Flutemetamol · For: Cardiac Amyloidosis
Sites: Toulouse, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- flushing265
- dyspnoea140
- back pain120
- dizziness91
- nausea87
- chest discomfort62
- headache51
- chest pain46
- cough39
- erythema39
- feeling hot37
- hot flush29
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 4 |
| 2018 | 7 |
| 2019 | 13 |
| 2020 | 7 |
| 2021 | 7 |
| 2022 | 7 |
| 2023 | 15 |
| 2024 | 76 |
| 2025 | 199 |
| 2026 | 185 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD, Buckley CJ, Heurling K, et al. · Acta Neuropathol Commun 2016 · Clinical Trial, Multicenter Study
- Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
Curtis C, Gamez JE, Singh U, et al. · JAMA Neurol 2015 · Clinical Trial, Phase III, Multicenter Study
- Tau PET probes for Alzheimer's disease detection and their structural characterization.
Chinnathambi S, Malik S, Chandrashekar M · Adv Protein Chem Struct Biol 2025 · Systematic Review, Research Support, N.I.H., Extramural
- BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
Sur C, Kost J, Scott D, et al. · Brain 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Ge Healthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.